DORAL (quazepam) by Galt Pharmaceuticals is tablet, like other central nervous system agents of the 14-benzodiazepine class, presumably exerts its effects by binding to stereo-specific receptors at several sites within the central nervous system (cns). Approved for insomnia characterized by difficulty falling asleep, frequent nocturnal awakenings, and/or early morning awakenings and 1 more indications. First approved in 1985.
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
DORAL (quazepam) is an oral benzodiazepine tablet approved in 1985 for treating insomnia characterized by difficulty falling asleep, frequent nocturnal awakenings, and early morning awakenings. It works by binding to stereo-specific CNS receptors, though the exact mechanism of action remains unknown.
Product is 1.6 years from patent expiration, signaling contraction phase with focus on defensive market tactics and cost management.
Tablet, like other central nervous system agents of the 14-benzodiazepine class, presumably exerts its effects by binding to stereo-specific receptors at several sites within the central nervous system (CNS). The exact mechanism of action is unknown.
Benzodiazepine
Worked on DORAL at Galt Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moGalt Pharmaceuticals is hiring 1 role related to this product
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Career opportunities with DORAL are concentrated in commercial/field roles through franchisees and alternative channels, reflecting its transition to mature market status. These roles emphasize sales execution and relationship management rather than product innovation or expansion.
13 open roles linked to this drug